Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOGAT: Mogamulizumab Plus Total Skin Electron Beam Therapy in Stage IB–IIB Cutaneous T-Cell Lymphoma
2022-502434-10-00Phase 2Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of mogamulizumab in cutaneous T-cell lymphoma (CTCL) and Sézary syndrome (SS), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression Free Survival Rate at 48 weeks (PFSR-48). Planned start Apr 2024; status: authorised.
02
Drugs
mogamulizumab
03
Conditions
cutaneous T-cell lymphoma (CTCL)Sézary syndrome (SS)
Beyond the preview
Go deeper on 2022-502434-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502434-10-00.